Our study shows that MCL1 inhibition might be a promising therapeutic option for hypereosinophilia patients specifically for CEL-NOS and MLN-Eo. This evidence concerns the gene MCL1 and Chronic Eosinophilic Leukemia, Not Otherwise Specified.